INNOSPEC INC.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 – BASIS OF PRESENTATION
The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934. Accordingly, they do not include all the information and notes necessary for a comprehensive presentation of financial position, results of operations and cash flows.
It is our opinion, however, that all adjustments (consisting of normal, recurring adjustments, unless otherwise disclosed) have been made which are necessary for a fair statement of the condensed consolidated financial statements. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed on February 18, 2026 (the “2025 Form 10-K”).
The results for the interim period covered by this report are not necessarily indicative of the results to be expected for the full year.
When we use the terms “Innospec,” “the Corporation,” “the Company,” “Registrant,” “the Group,” “we,” “us” and “our,” we are referring to Innospec Inc. and its consolidated subsidiaries unless otherwise indicated or the context otherwise requires.
NOTE 2 – SEGMENT REPORTING
The Company reports its financial performance based onthree reportable segments, which are Performance Chemicals, Fuel Specialties and Oilfield Services.
The Chief Operating Decision Maker (“CODM”) is the President and Chief Executive Officer (the Principal Executive Officer). The CODM evaluates the performance of the Company’s segments and makes strategic decisions relating to the Company's allocation of resources, based on the segments' gross profit and operating income.
The following table analyzes sales and other financial information by the Company’s reportable segments:
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| (in millions) | 2026 | 2025 | 2026 | 2025 |
| Net Sales: | ||||
| Personal Care | $110.5 | $103.9 | $319.6 | $309.4 |
| Home Care | 30.8 | 27.9 | 93.3 | 80.2 |
| Other | 39.2 | 39.0 | 127.3 | 123.4 |
| Performance Chemicals | 180.5 | 170.8 | 540.2 | 513.0 |
| Refinery and Performance | 126.5 | 120.2 | 384.7 | 362.4 |
| Other | 54.2 | 51.8 | 163.3 | 145.0 |
| Fuel Specialties | 180.7 | 172.0 | 548.0 | 507.4 |
| Oilfield Services | 112.4 | 99.1 | 330.0 | 302.0 |
| $473.6 | $441.9 | $1,418.2 | $1,322.4 | |
| Gross profit: | ||||
| Performance Chemicals | $34.0 | $25.8 | $95.4 | $91.6 |
| Fuel Specialties | 63.4 | 61.2 | 195.7 | 184.9 |
| Oilfield Services | 31.7 | 29.7 | 99.8 | 88.5 |
| Total gross profit | $129.1 | $116.7 | $390.9 | $365.0 |
| Operating income/(loss): | ||||
| Performance Chemicals | $16.9 | $9.2 | $44.0 | $43.3 |
| Fuel Specialties | 35.6 | 35.3 | 109.7 | 107.6 |
| Oilfield Services | 6.7 | 4.8 | 21.0 | 15.1 |
| Corporate costs | (18.6) | (18.2) | (62.5) | (56.8) |
| Adjustment to fair value of contingent consideration | 1.1 | 17.7 | 5.7 | 16.2 |
| Restructuring charge | — | (0.9) | — | (0.9) |
| Impairment of property, plant and equipment | — | (22.9) | — | (22.9) |
| Impairment of intangible assets | — | (19.1) | — | (19.1) |
| Profit on disposal of property, plant and equipment | — | — | — | 0.2 |
| Total operating income | $41.7 | $5.9 | $117.9 | $82.7 |
The difference between net sales and gross profit is defined as cost of goods sold. The difference between segmental gross profit and operating income/(expense) is split between selling, general and administrative expenses and research and development expenses.
The following table analyzes cost of goods sold by the Company’s reportable segments:
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| (in millions) | 2026 | 2025 | 2026 | 2025 |
| Performance Chemicals | $146.5 | $145.0 | $444.8 | $421.4 |
| Fuel Specialties | 117.3 | 110.8 | 352.3 | 322.5 |
| Oilfield Services | 80.7 | 69.4 | 230.2 | 213.5 |
| Total cost of goods sold | $344.5 | $325.2 | $1,027.3 | $957.4 |
The following table analyzes selling, general and administrative expenses and research and development expenses by the Company’s reportable segments:
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| (in millions) | 2026 | 2025 | 2026 | 2025 |
| Performance Chemicals | $17.1 | $16.6 | $51.4 | $48.3 |
| Fuel Specialties | 27.8 | 25.9 | 86.0 | 77.3 |
| Oilfield Services | 25.0 | 24.9 | 78.8 | 73.4 |
| Corporate | 18.6 | 18.2 | 62.5 | 56.8 |
| Total selling, general and administrative expenses and research and development expenses | $88.5 | $85.6 | $278.7 | $255.8 |
NOTE 3 – EARNINGS PER SHARE
Basic earnings per share is based on the weighted average number of common shares outstanding during the period. Diluted earnings per share includes the effect of options that are dilutive and outstanding during the period under the treasury stock method. Per share amounts are computed as follows:
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Numerator (in millions): | ||||
| Net income available to Innospec | $31.8 | $12.9 | $93.0 | $69.2 |
| Denominator (in thousands): | ||||
| Weighted average common shares outstanding | 24,631 | 24,834 | 24,684 | 24,914 |
| Dilutive effect of stock options and awards | 112 | 75 | 118 | 131 |
| Denominator for diluted earnings per share | 24,743 | 24,909 | 24,802 | 25,045 |
| Net income per share, basic: | $1.29 | $0.52 | $3.77 | $2.78 |
| Net income per share, diluted: | $1.29 | $0.52 | $3.75 | $2.76 |
In the three and nine months ended September 30, 2026, the average number of anti-dilutive options excluded from the calculation of diluted earnings per share were 21,340 and 21,687 (three and nine months ended September 30, 2025–57,824 and 23,875).
NOTE 4 – GOODWILL
The following table summarizes the goodwill movements in the year:
| (in millions) | 2026 |
|---|---|
| Opening balance at January 1 | $399.0 |
| Exchange effect | |
| Performance Chemicals | (1.5) |
| Fuel Specialties | (0.1) |
| Closing balance at September 30 | $397.4 |
NOTE 5 – OTHER INTANGIBLE ASSETS
The following table analyzes other intangible assets movements in the year:
| (in millions) | 2026 |
|---|---|
| Gross cost at January 1 | $373.3 |
| Additions | 5.0 |
| Exchange effect | (4.7) |
| Gross cost at September 30 | 373.6 |
| Accumulated amortization at January 1 | (305.6) |
| Amortization expense | (7.9) |
| Exchange effect | 2.4 |
| Accumulated amortization at September 30 | (311.1) |
| Net book amount at September 30 | $62.5 |
The amortization expense for the nine months ended September 30, 2026, was $7.9 million (nine months ended September 30, 2025, $9.3 million).
In 2026, we have capitalized $5.0 million in relation to the development of our internal-use software for a new Enterprise Resource Planning (“ERP”) system across all our regions. The project is now complete. The expenses capitalized include the acquisition costs for the software as well as the external consultancy costs and the internal employee costs relating to software development.
NOTE 6 – PENSION AND POST EMPLOYMENT BENEFITS
The Company maintains an unfunded defined benefit pension plan covering certain current and former employees in Germany (the “German plan”). The German plan is closed to new entrants and has no assets. As of September 30, 2026, we have recorded a liability of $8.9 million (December 31, 2025, $9.4 million).
The net periodic benefit/(cost) is shown in the following table:
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| (in millions) | 2026 | 2025 | 2026 | 2025 |
| Service credit/(cost) | $— | $— | $— | $(2.4) |
| Interest cost on projected benefit obligation | (0.1) | (0.1) | (0.3) | (0.2) |
| Amortization of actuarial net gains | 0.1 | — | 0.1 | — |
| Net periodic benefit/(cost) | $— | $(0.1) | $(0.2) | $(2.6) |
The prior year includes a service cost related to the now closed United Kingdom (U.K.) defined benefit pension scheme. The service cost has been recognized in selling, general and administrative expenses. All other items have been recognized within other income and expense.
In addition, we have obligations for post-employment benefits in some of our other European businesses. As of September 30, 2026, we have recorded a liability of $3.6 million (December 31, 2025, $3.8 million).
NOTE 7 – INCOME TAXES
As of January 1, 2026, the Company hadno unrecognized tax benefits, and there has beenno change in unrecognized tax benefits during the nine months ended September 30, 2026. Accordingly, there wasno accrual for uncertain tax positions as of September 30, 2026, and the Company recordedno associated interest or penalties. The Company does not expect any significant changes to this position over the next twelve months.
As of September 30, 2026, the Company and its U.S. subsidiaries remain open to examination by the IRS for years 2022 onwards under the statute of limitations. The Company’s subsidiaries in foreign tax jurisdictions are open to examination including Brazil (2021 onwards), Germany (2021 onwards), and the U.K. (2024 onwards).
NOTE 8 – LONG-TERM DEBT
As of September 30, 2026, and December 31, 2025, the Company hadnot drawn down on its revolving credit facility. During thethree and nine months ended September 30, 2026 and 2025, the Company didnot draw down or repay any borrowing on its revolving credit facility.
The Company continues to have available a $250.0 million multicurrency revolving credit facility until May 30, 2028.
NOTE 9 – PLANT CLOSURE PROVISIONS
The Company has continuing plans to remediate manufacturing facilities at sites around the world as and when those operations are expected to cease, or we are required to decommission the sites according to local laws and regulations. The liability for the estimated plant closure costs includes costs for asset retirement obligations and environmental remediation liabilities.
The principal site giving rise to asset retirement obligations is the manufacturing site at Ellesmere Port in the U.K.. There are also asset retirement obligations and environmental remediation liabilities in respect of our other manufacturing sites, which are relatively insignificant.
Movements in the provisions are summarized as follows:
| (in millions) | 2026 |
|---|---|
| Total at January 1 | $65.2 |
| Charge for the period | 4.1 |
| Utilized in the period | (3.6) |
| Exchange effect | (2.0) |
| Total at September 30 | 63.7 |
| Due within one year | (4.9) |
| Due after one year | $58.8 |
The charge for the nine months ended September 30, 2026, was $4.1 million (nine months ended September 30, 2025, $5.0 million). The current year charge represents the accounting accretion and a $1.4 million increase to the provisions for legacy operations in the U.K.. Amounts due within one year refer to provisions where expenditure is expected to arise within one year of the balance sheet date.
NOTE 10 – FAIR VALUE MEASUREMENTS
The following table presents the carrying amount and fair values of the Company’s financial assets and liabilities measured on a recurring basis:
| September 30, 2026 | December 31, 2025 | |||
|---|---|---|---|---|
| (in millions) | CarryingAmount | FairValue | CarryingAmount | FairValue |
| Assets | ||||
| Derivatives (Level 1 measurement): | ||||
| Other current and non-current assets: | ||||
| Emissions Trading Scheme credits | 6.1 | 6.1 | 3.2 | 3.2 |
| Foreign currency forward exchange contracts | 4.8 | 4.8 | 3.4 | 3.4 |
| Liabilities | ||||
| Non-financial liabilities (Level 3 measurement): | ||||
| Other current and non-current liabilities: | ||||
| Acquisition-related contingent consideration | 3.0 | 3.0 | 8.3 | 8.3 |
The following methods and assumptions were used to estimate the fair values:
Emissions Trading Scheme credits: The fair value is determined by the open market pricing at the end of the reporting period.
Foreign currency forward exchange contracts: The fair value of derivatives relating to foreign currency forward exchange contracts are derived from current settlement prices and comparable contracts using current assumptions. Foreign currency forward exchange contracts primarily relate to contracts entered into to hedge future known transactions or hedge balance sheet net cash positions. The movements in the carrying amounts and fair values of these contracts are largely due to changes in exchange rates against the U.S. dollar.
Acquisition-related contingent consideration: Contingent consideration payable in cash is discounted to its fair value at each balance sheet date. Where contingent consideration is dependent upon pre-determined financial targets, an estimate of the fair value of the likely consideration payable is made at each balance sheet date. The contingent consideration payable has been calculated based on the latest forecast. The movement in the current year relates to a $6.3 million reduction in the fair value of the expected payable relating to the acquisition of QGP Química Geral (“QGP”) in our Performance Chemicals segment and a small acquisition in our Oilfield Services segment, partially offset by an accretion charge of $0.5 million and the impact of foreign exchange of $0.5 million.
NOTE 11 – DERIVATIVE INSTRUMENTS AND RISK MANAGEMENT
The Company enters into various foreign currency forward exchange contracts to minimize currency exchange rate exposure from expected future cash flows. As of September 30, 2026, the contracts have maturity dates of up to two years at the date of inception. These foreign currency forward exchange contracts have not been designated as hedging instruments, and their impact on the income statement for the nine months ended September 30, 2026, was a gain of $1.1 million (nine months ended September 30, 2025, a loss of $3.6 million). The gain or loss has been recorded in other income or expense.
NOTE 12 – CONTINGENCIES
Legal matters
We are involved from time to time in claims and legal proceedings that result from, and are incidental to, the conduct of our business including business and commercial litigation, and employee and product liability claims.
As reported in our Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Form 10-K"), we have incurred financial losses and lodged a civil and criminal legal claim related to a misappropriation of inventory in Brazil. At the time of filing, there have been no significant developments to report in relation to the claims being made. Consistent with prior quarters, a corresponding asset for the potential legal or insurance recoveries has not been recorded for the resulting financial losses arising from this matter.
In addition, unrelated to the Brazil matter, in the unlikely event there are an unexpectedly large number of individual claims or proceedings with an adverse resolution, this could in the aggregate have a material adverse effect on the results of operations for a particular year or quarter.
Guarantees
The Company and certain of the Company’s consolidated subsidiaries are contingently liable for certain obligations of affiliated companies primarily in the form of guarantees of debt and performance under contracts entered into as a normal business practice. This includes guarantees of non-U.S. excise taxes and customs duties. As of September 30, 2026, such guarantees, which are not recognized as liabilities in the condensed consolidated financial statements, amounted to $7.3 million (December 31, 2025, $6.0 million). The remaining terms of the fixed maturity guarantees are up to 6 years, with some further guarantees having no fixed expiry date.
Under the terms of the guarantee arrangements, generally the Company would be required to fulfil the obligations should the affiliated company fail to fulfil its obligations under the arrangements. In some cases, the guarantee arrangements have recourse provisions that would enable the Company to recover any payments made under the terms of the guarantees from securities held of the guaranteed parties’ assets.
The Company and its affiliates have numerous long-term sales and purchase commitments in their various business activities, which are expected to be fulfilled with no adverse consequences material to the Company.
NOTE 13 – STOCK-BASED COMPENSATION PLANS
The following table summarizes the transactions of the Company’s share-based compensation for 2026 and 2025:
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| (in millions) | 2026 | 2025 | 2026 | 2025 |
| Stock options | $1.4 | $0.9 | $5.2 | $5.0 |
| Stock equivalent units | 2.3 | 0.7 | 5.3 | 1.2 |
| Total | $3.7 | $1.6 | $10.5 | $6.2 |
The following table summarizes the transactions of the Company’s share-based compensation plans for thenine months ended September 30, 2026.
| Number ofshares | WeightedAverageGrant-DateFair Value | |
|---|---|---|
| Nonvested at December 31, 2025 | 431,297 | $109.5 |
| Granted | 350,477 | $59.5 |
| Vested | (96,340) | $91.5 |
| Forfeited | (57,607) | $100.8 |
| Nonvested at September 30, 2026 | 627,827 | $85.4 |
For the awards granted with market conditions, a Monte Carlo model has been used to calculate the grant-date fair value. For all other awards, a fair market value methodology or a Black-Scholes model has been used to calculate the grant-date fair value.
The awards granted with market and non-market conditions include performance measures that can result in a maximum 200% vesting for the number of stock options granted. The predicted vesting has been reflected in the grant-date fair value calculation but has not been reflected for the number of awards granted, as shown in the table above.
As of September 30, 2026, there was $26.3 million of total unrecognized compensation cost related to nonvested share-based compensation arrangements. That cost is expected to be recognized over a weighted-average period of 2.1 years.
NOTE 14 – RECLASSIFICATIONS OUT OF ACCUMULATED OTHER COMPREHENSIVE LOSS
There wereno reclassifications out of accumulated other comprehensive loss (“AOCL”) for thenine months ended September 30, 2026.
Changes in AOCL for thenine months ended September 30, 2026, net of tax, were:
| (in millions) | DefinedBenefitPensionPlan Items | CumulativeTranslationAdjustments | Total |
|---|---|---|---|
| Balance at December 31, 2025 | $0.9 | $(35.6) | $(34.7) |
| Other comprehensive income/(loss) before reclassifications | — | (15.4) | (15.4) |
| Amounts reclassified from AOCL | — | — | — |
| Total other comprehensive income/(loss) | — | (15.4) | (15.4) |
| Balance at September 30, 2026 | $0.9 | $(51.0) | $(50.1) |
There wereno reclassifications out of AOCL for thenine months ended September 30, 2025.
Changes in AOCL for thenine months ended September 30, 2025, net of tax, were:
| (in millions) | DefinedBenefitPensionPlan Items | CumulativeTranslationAdjustments | Total |
|---|---|---|---|
| Balance at December 31, 2024 | $— | $(91.0) | $(91.0) |
| Other comprehensive income/(loss) before reclassifications | — | 56.0 | 56.0 |
| Amounts reclassified from AOCL | — | — | — |
| Total other comprehensive income/(loss) | — | 56.0 | 56.0 |
| Balance at September 30, 2025 | $— | $(35.0) | $(35.0) |
NOTE 15 – RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
There were no new accounting pronouncements relevant to Innospec in the quarter.
NOTE 16 – RELATED PARTY TRANSACTIONS
Mr. David F. Landless has been a non-executive director of the Company since January 1, 2016, and is a non-executive director of Ausurus Group Limited which owns European Metal Recycling Limited (“EMR”) which from time to time purchases scrap metal from the Company. The Company has sold less than $0.1 million of scrap metal to EMR in thenine months ended September 30, 2026 (nine months ended September 30, 2025, less than $0.1 million). A tendering process is operated periodically to select the best buyer for the sale of scrap metal by the Company. As of September 30, 2026, EMR owednil for scrap metal purchased from the Company (December 31, 2025, nil).
Item 2 Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Three and Nine Months Ended September 30, 2026
This discussion should be read in conjunction with our unaudited interim condensed consolidated financial statements and the notes thereto.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.